MALVERN, Pa.--(BUSINESS WIRE)--Human Genome Sciences (HGS: NASDAQ: HGSI) announced that BENLYSTA TM met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback